Product Reports Resources Pricing Login Book a demo

Evozyne

Biotech & Life Sciences · Chicago, United States · Founded 2020

Generative AI-powered drug discovery platform and product development MoreLess

Evozyne is a pioneering biotech startup focused on creating novel protein systems to address some of the world's most pressing health challenges. The company leverages the natural principles of evolution to develop advanced proteins, which they refer to as "Natural Machines." These proteins are designed to perform specific functions at an unprecedented level of efficiency, paving the way for new therapeutic solutions and commercial-scale applications.

Evozyne primarily serves clients in the pharmaceutical and biotechnology sectors, including companies involved in drug discovery and development. By offering innovative protein solutions, Evozyne aims to enhance the efficacy and safety of therapeutic products, thereby contributing to a healthier world.

Operating in the highly specialized market of protein engineering and synthetic biology, Evozyne stands out due to its unique approach of using evolutionary principles to solve complex biological problems. This market is characterized by rapid advancements and high demand for cutting-edge solutions that can address unmet medical needs.

Evozyne's business model revolves around research and development (R&D) and strategic partnerships. The company invests heavily in R&D to continuously innovate and refine its protein systems. Revenue is generated through collaborations with pharmaceutical companies, licensing agreements, and potentially through the commercialization of proprietary therapeutic products developed using their technology.

The leadership team at Evozyne includes experts with extensive backgrounds in molecular engineering, computational biology, and drug discovery. Their scientific advisory board comprises distinguished professors and researchers from top institutions, ensuring that the company remains at the forefront of scientific innovation.

In summary, Evozyne is a biotech startup that creates advanced protein systems to solve critical health challenges, serving pharmaceutical and biotech clients through a robust R&D-focused business model.

Keywords: biotech, protein engineering, synthetic biology, drug discovery, therapeutic development, evolution, R&D, pharmaceutical, innovation, health solutions.

Company overview

Evozyne company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2020
Headquarters
Chicago, United States
Employees
54
Open positions
2
Dealroom signal
70.4
client focusb2btechnologyArtificial IntelligencetechnologyDeep Techsub industryPharmaceuticalsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorDrug DevelopmentsectorCore AIsectorSpinoutsectorBiotech and PharmasectorGenerative AIsectorAI Drug Discovery

Valuation & funding

Evozyne funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Sep 2023 $81M $324M Valor Equity Partners · NVentures · Fidelity Investments · OrbiMed
SERIES AOther financing Apr 2021 $54M $217M Undisclosed
EARLY VCOther financing Apr 2020 $9.2M $37M Undisclosed
SPINOUTOther financing Jan 2020 $0 The University of Chicago
Showing 4 recorded eventsUnlock the complete deal history →

Growth signals

Evozyne website traffic

Latest recorded traffic for Evozyne is 2.7K monthly website visits, up 35% over the last three months. Evozyne's team grew 0% over the past year.

Latest monthly visits2.7K 3-month web change+35% 1-year team growth0%
Monthly website visits67 observations · Dec 2020–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Evozyne compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Proxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation New York City, United States Operational 77 $80M $320M
Superluminal MedicinesGenerative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created Boston, United States Operational
VilyaDeveloping a novel class of drugs that precisely target the biology of disease Seattle, United States Operational
Menten AILeverages synthetic biology, machine learning and quantum computing to create new proteins not found in nature for diverse applications in the pharmaceutical and chemical industries San Francisco, United States Operational
Genesis TherapeuticsUnifying AI and Biotech We're pairing proven drug developers with the industry's most advanced small molecule discovery platform, to accelerate and optimize the development of new medicines Burlingame, United States Operational
AbSciThe global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry Vancouver, United States Operational
Xaira TherapeuticsIntegrated biotechnology company focusing on leveraging artificial intelligence to transform drug discovery and development Brisbane, United States Operational
AutomeratxDeveloping the next evolution in degradation platforms Singapore Operational
Showing 8 of the closest matchesCompare every metric →

Talent graph

Evozyne's talent

Book a demo to see the people
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

6 investors on Evozyne's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 5 investors entered at this stage
Other known 1 additional known investor
The University of Chicago

Global footprint

Where Evozyne has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

In the news

Latest news about Evozyne

Recent press, funding announcements, and product moves mentioning Evozyne — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Evozyne

An AI-synthesized read of the highest-engagement posts about Evozyne on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Evozyne’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.